Aytu BioPharma, Inc. (AYTU)

Market Cap	10.61M
Revenue (ttm)	104.12M
Net Income (ttm)	-32.30M
Shares Out	5.52M
EPS (ttm)	-11.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	95,408
Open	1.68
Previous Close	1.65
Day's Range	1.66 - 1.93
52-Week Range	1.38 - 4.80
Beta	-0.37
Analysts	Strong Buy
Price Target	12.50 (+551.04%)
Earnings Date	Nov 13, 2023

About AYTU

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates into two segments Rx segment and Consumer Health segment. The Rx segment consisting of prescription pharmaceutical products sold through third party wholesalers. The Consumer Health segment, which consists of various consumer health products sell directly to consumers. It also offers Adzenys XR-ODT for the treatment of attention ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Joshua R. Disbrow
• Employees: 164
• Stock Exchange: NASDAQ
• Ticker Symbol: AYTU

Financial Performance

In 2022, Aytu BioPharma's revenue was $96.67 million, an increase of 47.29% compared to the previous year's $65.63 million. Losses were -$110.17 million, 89.0% more than in 2021.

Analyst Forecast

According to 2 analysts, the average rating for AYTU stock is "Strong Buy." The 12-month stock price forecast is $12.5, which is an increase of 551.04% from the latest price.

Price Target

$12.5

(551.04% upside)

Analyst Consensus: Strong Buy